BACKGROUND: The increased expression of the fibroblast growth factor receptor 4 (FGFR4) has been identified in many human cancers. Recently, a single nucleotide polymorphism changing the sense codon 388 from glycine to arginine was identified in the FGFR4 gene. The FGFR4 Arg(388) allele was found to be associated with a poor prognosis for positive node breast cancer, high-grade soft-tissue sarcoma, colon carcinoma, and head and neck squamous cell carcinoma (HNSCC). METHODS: We decided to verify the impact of the FGFR4 Arg(388) allele on survival as well as its association with histoclinical data in 75 cases of HNSCC. The FGFR4 Arg(388) allele was detected by PCR-RFLP and DNA sequencing. RESULTS: The FGFR4 Arg(388) allele was detected in 42.5% of the tumors (37% heterozygous Gly/Arg and 5.5% homozygous Arg/Arg). The presence of at least one Arg allele was significantly correlated with reduced overall survival after 24 months of follow-up. The cases involving the Arg allele presented an increased mortality risk of 2.2 if compared to the non-carrier cases. CONCLUSION: The FGFR4 Arg(388) allele is associated with a shortened survival.
BACKGROUND: The increased expression of the fibroblast growth factor receptor 4 (FGFR4) has been identified in many humancancers. Recently, a single nucleotide polymorphism changing the sense codon 388 from glycine to arginine was identified in the FGFR4 gene. The FGFR4Arg(388) allele was found to be associated with a poor prognosis for positive node breast cancer, high-grade soft-tissue sarcoma, colon carcinoma, and head and neck squamous cell carcinoma (HNSCC). METHODS: We decided to verify the impact of the FGFR4Arg(388) allele on survival as well as its association with histoclinical data in 75 cases of HNSCC. The FGFR4Arg(388) allele was detected by PCR-RFLP and DNA sequencing. RESULTS: The FGFR4Arg(388) allele was detected in 42.5% of the tumors (37% heterozygous Gly/Arg and 5.5% homozygous Arg/Arg). The presence of at least one Arg allele was significantly correlated with reduced overall survival after 24 months of follow-up. The cases involving the Arg allele presented an increased mortality risk of 2.2 if compared to the non-carrier cases. CONCLUSION: The FGFR4Arg(388) allele is associated with a shortened survival.
Authors: Owen M Wilkins; Alexander J Titus; Lucas A Salas; Jiang Gui; Melissa Eliot; Rondi A Butler; Erich M Sturgis; Guojun Li; Karl T Kelsey; Brock C Christensen Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-06-07 Impact factor: 4.254
Authors: Wendong Yu; Shu Feng; Olga Dakhova; Chad J Creighton; Yi Cai; Jianghua Wang; Rile Li; Anna Frolov; Gustavo Ayala; Michael Ittmann Journal: Clin Cancer Res Date: 2011-05-27 Impact factor: 12.531
Authors: Nami Sugiyama; Markku Varjosalo; Pipsa Meller; Jouko Lohi; Kui Ming Chan; Zhongjun Zhou; Kari Alitalo; Jussi Taipale; Jorma Keski-Oja; Kaisa Lehti Journal: Proc Natl Acad Sci U S A Date: 2010-08-23 Impact factor: 11.205
Authors: Sarah B Whittle; Sahily Reyes; Melissa Du; Monica Gireud; Linna Zhang; Sarah E Woodfield; Michael Ittmann; Michael E Scheurer; Andrew J Bean; Peter E Zage Journal: J Pediatr Hematol Oncol Date: 2016-03 Impact factor: 1.289
Authors: Christine Heinzle; Zeynep Erdem; Jakob Paur; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian Journal: Curr Pharm Des Date: 2014 Impact factor: 3.116
Authors: Christine Heinzle; Andrea Gsur; Monika Hunjadi; Zeynep Erdem; Christine Gauglhofer; Stefan Stättner; Josef Karner; Martin Klimpfinger; Friedrich Wrba; Andrea Reti; Balazs Hegedus; Andreas Baierl; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian Journal: Cancer Res Date: 2012-09-12 Impact factor: 12.701